Quarterly report pursuant to Section 13 or 15(d)

REVENUES - Disaggregated (Details)

v3.24.3
REVENUES - Disaggregated (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Disaggregation of Revenue [Line Items]        
Total revenues $ 55,307 $ 28,134 $ 121,682 $ 81,090
Gross product sales        
Disaggregation of Revenue [Line Items]        
Total revenues 56,322 38,585 143,728 105,239
Discounts and allowances        
Disaggregation of Revenue [Line Items]        
Total revenues (17,395) (11,456) (45,348) (30,484)
Product sales, net        
Disaggregation of Revenue [Line Items]        
Total revenues 38,927 27,129 98,380 74,755
License        
Disaggregation of Revenue [Line Items]        
Total revenues 10,000   10,000  
Milestone        
Disaggregation of Revenue [Line Items]        
Total revenues   75   75
Delivery of drug supplies, royalty and others        
Disaggregation of Revenue [Line Items]        
Total revenues 6,380 930 13,302 5,260
Revenues from collaborations        
Disaggregation of Revenue [Line Items]        
Total revenues $ 16,380 $ 1,005 $ 23,302 5,335
Government contracts        
Disaggregation of Revenue [Line Items]        
Total revenues       $ 1,000